Clinical Trial Update: Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy [Phase 4]

View source ↗

Summary

Phase 4 trial update on intensive treatment for hormone receptor-negative, HER2-negative breast cancer with positive lymph node residual disease after neoadjuva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Tao OUYANG | Conditions: Primary Breast Cancer | Phase 4 | Status: UNKNOWN